A collaborative center for assay development and high throughput screening in all phases of project conception, development, validation, screening, and post-screen hit validation.
The High Throughput Bioscience (HTB) center consists of qualified members with advanced biology, chemistry, and engineering training. We have experience in target identification and validation, assay development, high throughput screening, high content screening, laboratory automation, and management of scientific collaborations. We assist our collaborators in assay development, assay validation, miniaturization, and automation. We implement and manage HTS projects; manage and utilize whole genome siRNA libraries (human and mouse); evaluate and develop novel drug discovery technologies; and provide training to the St. Jude community. The following overview can represent the collaborative process:
These systems are made up of various pieces of equipment that work together using integration software to fully automate assays/workflows that were previously 100% manual or semi-automated. Before coming to St. Jude, I had worked with platforms that were considered semi-automatic, but nothing as robust as what I have worked with in HTB. Being able to see the impact of my work on the lives of many is one of the things that makes my job so fulfilling.
Marlon Trotter, HTS Automation Technologist
Dr. Taosheng Chen is a Full Member at the Department of Chemical Biology & Therapeutics and the Director of the HTB Center. He received his BSc and MS degrees from Fudan University, China, and completed his Ph.D. studies from the University of Vermont and postdoctoral studies from the University of Virginia. Before joining St. Jude in 2006, Dr. Chen was a Senior Research Investigator at Bristol-Myers Squibb and a Research Scientist at SAIC-Frederick, National Cancer Institute. He serves on journal Editorial Boards and NIH study sections (chairperson of the DMP study section). In 2009, Dr. Chen published his first book, “A Practical Guide to Assay Development and High-Throughput Screening in Drug Discovery.” In 2017, he became one of the 39 inaugural Fellow Members of the Society for Laboratory Automation and Screening (SLAS). In addition to directing the HTB Center, his NIH-funded research laboratory studies the transcriptional regulation of drug responses.
There are eight of us, so we can cover projects from multiple directions. The brainstorming session we have are fantastic. We can take someone's idea and turn it into something reproducible and screenable. We have all the tools of a well-funded biotech which makes us incredibly flexible. If you can imagine it, we can find a way to make it happen.
Jonathan Low, Senior Scientist